Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 15, 2025 • 3:00 PM ET

Date/Time Source News Release
06/02/2025 08:00 AM EDT GlobeNewswire Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
05/20/2025 08:00 AM EDT GlobeNewswire Esperion to Participate in Upcoming June Investor Conferences
05/12/2025 08:00 AM EDT GlobeNewswire Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
05/09/2025 08:00 AM EDT GlobeNewswire Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference
05/08/2025 04:30 PM EDT GlobeNewswire Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/08/2025 06:32 AM EDT Canada Newswire HLS Therapeutics Announces Q1 2025 Financial Results
05/08/2025 06:30 AM EDT GlobeNewswire Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
05/08/2025 06:30 AM EDT Canada Newswire HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada
05/06/2025 06:00 AM EDT GlobeNewswire Esperion Reports First Quarter 2025 Financial Results
04/25/2025 08:00 AM EDT GlobeNewswire Esperion to Participate in The Citizens Life Sciences Conference
Page

Additional News

As of June 15, 2025 • 3:00 PM ET

Date/Time Source News Release
06/14/2025 07:03 AM EDT SeekingAlpha Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?
06/05/2025 11:30 AM EDT Zacks Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?
05/25/2025 04:50 AM EDT SeekingAlpha Why AstraZeneca May Be 2025's Most Underrated Pharma Stock
05/08/2025 10:04 AM EDT SeekingAlpha Esperion and HLS partner to commercialize heart disease treatments in Canada
05/07/2025 12:09 PM EDT Zacks ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
05/06/2025 10:50 AM EDT SeekingAlpha Esperion outlines Q2 prescription growth, targets triple combo launch by 2027
05/06/2025 10:49 AM EDT SeekingAlpha Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript
05/06/2025 07:15 AM EDT Zacks Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates
05/06/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Tuesday, May 6th, 2025
05/06/2025 06:02 AM EDT SeekingAlpha Esperion Therapeutics GAAP EPS of -$0.21 misses by $0.06, revenue of $64.99M beats by $10.8M
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.